Zakowiecki, D.; Edinger, P.; Papaioannou, M.; Wagner, M.; Hess, T.; Paszkowska, J.; Staniszewska, M.; Myslitska, D.; Smolenski, M.; Dobosz, J.;
et al. Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban. Pharmaceutics 2024, 16, 1485.
https://doi.org/10.3390/pharmaceutics16111485
AMA Style
Zakowiecki D, Edinger P, Papaioannou M, Wagner M, Hess T, Paszkowska J, Staniszewska M, Myslitska D, Smolenski M, Dobosz J,
et al. Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban. Pharmaceutics. 2024; 16(11):1485.
https://doi.org/10.3390/pharmaceutics16111485
Chicago/Turabian Style
Zakowiecki, Daniel, Peter Edinger, Markos Papaioannou, Michael Wagner, Tobias Hess, Jadwiga Paszkowska, Marcela Staniszewska, Daria Myslitska, Michal Smolenski, Justyna Dobosz,
and et al. 2024. "Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban" Pharmaceutics 16, no. 11: 1485.
https://doi.org/10.3390/pharmaceutics16111485
APA Style
Zakowiecki, D., Edinger, P., Papaioannou, M., Wagner, M., Hess, T., Paszkowska, J., Staniszewska, M., Myslitska, D., Smolenski, M., Dobosz, J., Garbacz, G., & Haznar Garbacz, D.
(2024). Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban. Pharmaceutics, 16(11), 1485.
https://doi.org/10.3390/pharmaceutics16111485
